Indian Pharma Cos 19th in Biopharmaceutical Competitiveness & Investment Survey

Indian pharmaceutical companies have ranked low at 19th position with an overall score of 59 out of 100 among in the Biopharmaceutical Competitiveness & Investment (BCI) Survey. 
●    The survey of 28 countries was commissioned by the Pharmaceutical Research and Manufacturers of America and executed by the Pugatch Consilium. 
●    It was third edition of survey. 
●    Five metrics were used to determine rankings of countries. 
●    They are scientific capabilities and infrastructure; clinical research conditions and framework; regulatory system; market access and financing; and effective intellectual property protections.
●    It had looked at biomedical innovation and its influencers, like intellectual property protection for investments in the pharmaceutical sector. 
●    It had categorized countries into two groups viz. mature markets like UK US, and Germany, and newcomers like China, India and Brazil. 
●    Markets provide advanced intellectual property protection, highly streamlined regulatory framework and favourable tax conditions with some exceptions.